I'm glad to see this being covered - because, frankly, this is a death-blow to collaborative science - however, the assumption of good faith in any of these decisions by reporters is mind-boggling.
This is happening for one reason - to assure top-down control of what gets funded and what does not.
Kristian G. Andersen
The US NIH is stepping back from 'top-down' science.
My latest analysis for @nature.com shows that funding calls have plummeted by 90%, funneling billions into broad, 'investigator-initiated' ideas, rather than targeted, agency-driven ones.
A massive shift for the American biomedical enterprise.
US biomedical funding behemoth says the approach will boost innovation, but some researchers worry that understudied areas of science will suffer.
